Dermapharm Holding Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Hans-Georg Feldmeier

Chief Executive Officer (CEO)

€1.4m

Compensación total

Porcentaje del salario del CEO	59.7%
Permanencia del CEO	6.8yrs
Participación del CEO	n/a
Permanencia media de la dirección	1.7yrs
Promedio de permanencia en la Junta Directiva	6.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Hans-Georg Feldmeier en comparación con los beneficios de Dermapharm Holding?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	€1m	€821k	€62m
Sep 30 2023	n/a	n/a	€95m
Jun 30 2023	n/a	n/a	€123m
Mar 31 2023	n/a	n/a	€146m
Dec 31 2022	€1m	€800k	€134m
Sep 30 2022	n/a	n/a	€176m
Jun 30 2022	n/a	n/a	€185m
Mar 31 2022	n/a	n/a	€211m
Dec 31 2021	€1m	€800k	€210m
Sep 30 2021	n/a	n/a	€162m
Jun 30 2021	n/a	n/a	€123m
Mar 31 2021	n/a	n/a	€95m
Dec 31 2020	€736k	€411k	€86m

Compensación vs. Mercado: La compensación total de Hans-Georg($USD1.48M) está por debajo de la media de empresas de tamaño similar en el mercado UK ($USD2.33M).

Compensación vs. Ingresos: La compensación de Hans-Georg ha sido consistente con los resultados de la empresa en el último año.

CEO

Hans-Georg Feldmeier

6.8yrs

Permanencia

€1,375,000

Compensación

Dr. Hans-Georg Feldmeier is the Chief Executive Officer and Chairman of the Management Board at Dermapharm Holding SE and also serves as Member of the Management Board from August 2017.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Hans-Georg Feldmeier	CEO & Chairman of the Management Board	6.8yrs	€1.38m	sin datos
Christof Dreibholz	CFO, Chief Compliance Officer & Member of Management Board	1.5yrs	€617.00k	sin datos
Andreas Eberhorn	Chief Marketing Officer & Member of Management Board	1.7yrs	€612.00k	sin datos
Britta Hamberger	Head of Investor Relations & Corporate Communications	no data	sin datos	sin datos

1.7yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 0A5J no se considera experimentado ( 1.6 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Lothar Lanz	Independent Member of Supervisory Board	6.3yrs	€80.00k	sin datos
Wilhelm Beier	Chairman of the Supervisory Board	6.8yrs	€80.00k	sin datos
Erwin Kern	Independent Vice Chairman of the Supervisory Board	6.8yrs	€80.00k	sin datos

6.8yrs

Permanencia media

67yo

Promedio de edad

Junta con experiencia: La junta directiva de 0A5J se considera experimentada (6.7 años de antigüedad promedio).

Dermapharm Holding Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Dermapharm Holding SE, Annual General Meeting, Jun 27, 2024

Dermapharm Holding SE Announces Executive Changes

Recent updates

Dermapharm Holding SE to Report Q1, 2024 Results on May 15, 2024

Full year 2023 earnings released: EPS: €1.16 (vs €2.49 in FY 2022)

Dermapharm Holding SE, Annual General Meeting, Jun 27, 2024

Dividend of €0.88 announced

Dermapharm Holding SE to Report Fiscal Year 2023 Results on Mar 28, 2024

New minor risk - Financial position

Third quarter 2023 earnings released: EPS: €0.46 (vs €0.98 in 3Q 2022)

Now 21% undervalued after recent price drop

Second quarter 2023 earnings released: €0.17 loss per share (vs €0.27 profit in 2Q 2022)

Upcoming dividend of €1.05 per share at 2.3% yield

Full year 2022 earnings released: EPS: €2.49 (vs €3.89 in FY 2021)

Third quarter 2022 earnings released: EPS: €0.98 (vs €1.15 in 3Q 2021)

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: €0.27 (vs €0.74 in 2Q 2021)

Dermapharm Holding SE Announces Executive Changes

Dermapharm Holding SE Provides Earnings Guidance for the Full Year 2022

Upcoming dividend of €2.17 per share

First quarter 2022 earnings released: EPS: €0.69 (vs €0.67 in 1Q 2021)

Dermapharm Holding SE Provides Earnings Guidance for the Full Year 2022

Full year 2021 earnings released: EPS: €3.89 (vs €1.59 in FY 2020)

Dermapharm Holding SE Proposes Dividend for the Year 2021

Investor sentiment deteriorated over the past week

Dermapharm Holding SE (XTRA:DMP) completed the acquisition of C³ - Cannabinoid Compound Company Gmbh from Canopy Growth Corporation (TSX:WEED).

Dermapharm Holding SE (XTRA:DMP) completed the acquisition of C³ - Cannabinoid Compound Company Gmbh from Canopy Growth Corporation (TSX:WEED).

Dermapharm Holding SE (XTRA:DMP) entered into an agreement to acquire C3 - Cannabionoid Compound Company GmbH from Canopy Growth Corporation (TSX:WEED) for approximately €120 million.

Third quarter 2021 earnings released: EPS €1.15 (vs €0.42 in 3Q 2020)

Second quarter 2021 earnings released: EPS €0.74 (vs €0.22 in 2Q 2020)

First quarter 2021 earnings released: EPS €0.67 (vs €0.50 in 1Q 2020)

Dermapharm Confirms Earnings Guidance for 2021

Full year 2020 earnings released: EPS €1.59 (vs €1.43 in FY 2019)

Dermapharm Holding SE Provides Revenue Guidance for Fiscal 2021

Investor sentiment improved over the past week

Dermapharm Holding SE Expects the Collaboration with BioNTech SE for the Production of the Covid-19 Vaccine Comirnaty

New 90-day high: €63.75

New 90-day high: €58.25

Market bids up stock over the past week

Revenue misses expectations

Third quarter 2020 earnings released: EPS €0.42

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad